Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Meclofenamate Sodium (Meclonax; Meclomen; INF-4668; INF4668; CI 583; CI-583; Meclodium; Meclofenamic acid sodium) is a potent nonsteroidal anti-inflammatory drug (NSAID), acting as a dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM, respectively. It is used in the treatment of joint, muscular pain, arthritis and dysmenorrhea. Meclofenamate sodium is a potent nonsteroidal antiinflammatory agent, specifically inhibits chemotactic factor-induced human polymorphonuclear leukocyte functions: chemotaxis, degranulation, and generation of superoxide anion radicals. These effects of MSM were found to be dependent upon the concentrations of drug not bound to albumin (free drug), and were caused by its ability to interfere at both a receptor and post-receptor level.
References |
J Mol Cell Cardiol.2016May;94:131-44;
|
---|
Molecular Formula |
C14H11CL2NO2.NA
|
|
---|---|---|
Molecular Weight |
318.13
|
|
CAS # |
6385-02-0
|
|
Related CAS # |
Meclofenamic acid;644-62-2
|
|
SMILES |
ClC1=C(C([H])([H])[H])C([H])=C([H])C(=C1N([H])C1=C([H])C([H])=C([H])C([H])=C1C(=O)[O-])Cl.[Na+]
|
|
InChi Key |
QHJLLDJTVQAFAN-UHFFFAOYSA-M
|
|
InChi Code |
InChI=1S/C14H11Cl2NO2.Na.H2O/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);;1H2/q;+1;/p-1
|
|
Chemical Name |
sodium 2-((2,6-dichloro-3-methylphenyl)amino)benzoate hydrate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1434 mL | 15.7168 mL | 31.4337 mL | |
5 mM | 0.6287 mL | 3.1434 mL | 6.2867 mL | |
10 mM | 0.3143 mL | 1.5717 mL | 3.1434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02429570 | Active, not recruiting | Drug: Meclofenamate | Recurrent Brain Metastases Progressive Brain Metastases |
Memorial Sloan Kettering Cancer Center |
April 22, 2015 | Not Applicable |
NCT02930005 | Completed Has Results | Drug: Meclofenamic acid Drug: Pentosan polysulfate sodium |
Psychotic Disorders Schizophrenia |
The University of Texas Health Science Center, Houston |
August 7, 2015 | Phase 2 |
The antiproliferative effects of MA and/or GE on gefitinib-resistant NSCLC cells. (A–D) The parental PC9 and H292 as well as gefitinib-resistant PC9/GR and H292/GR cells were treated with various concentrations of GE or MA; the antiproliferative effects were determined by MTT assay following 48 h of incubation. Cells were treated with GE and MA as a single agent or in combination for 48 h, and MTT assays were used to analyze the cell viability. The Chou–Talalay method was conducted to calculate the combination index (CI); a CalcuSyn software were used to analyze the data. (E–H) illustrate the combination ratio/viability, while (I–L) show the fraction affected/combination index. Data are presented for at least three independent repetitions and were illustrated as mean ± SD. td> |
MA and GE synergistically induced caspase-3-associated apoptosis in gefitinib-resistant NSCLC cells. Apoptotic cells in PC9/GR (A) and H292/GR (B) exposed to the single drugs or combination are presented in dot blot. Western blot results show dynamic caspase-3 face after PC9/GR (C) or H292/GR (D) exposed to single or combination drugs. td> |
MA and GE synergistically inhibited the activity of the EGFR-related signaling pathway. Western blot results showed the expression of p-EGFR, p-Akt, and p-ERK1/2 in PC9/GR (A) and H292/GR (B) cells exposed to MA and GE for single or combination use. (C–H) showed the statistical analysis of the Western blot results (A, B). Data are presented for at least three independent repetitions and were illustrated as mean ± SD. ***p < 0.001, ****p < 0.0001. td> |